MX2022001219A - Dominios variables humanos modificados. - Google Patents

Dominios variables humanos modificados.

Info

Publication number
MX2022001219A
MX2022001219A MX2022001219A MX2022001219A MX2022001219A MX 2022001219 A MX2022001219 A MX 2022001219A MX 2022001219 A MX2022001219 A MX 2022001219A MX 2022001219 A MX2022001219 A MX 2022001219A MX 2022001219 A MX2022001219 A MX 2022001219A
Authority
MX
Mexico
Prior art keywords
variable domains
modified human
human variable
phages
humanized
Prior art date
Application number
MX2022001219A
Other languages
English (en)
Inventor
Peter Brian Silverman
Robert Arjen Kramer
Alexander Berthold Henrik Bakker
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2022001219A publication Critical patent/MX2022001219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona polipéptidos que comprenden dominios variables de cadena pesada de inmunoglobulina humanos, humanizados o quiméricos modificados. También se proporcionan los anticuerpos correspondientes, variantes, fragmentos, ácidos nucleicos, vectores, fagos, bibliotecas, métodos y kits.
MX2022001219A 2019-08-07 2020-08-04 Dominios variables humanos modificados. MX2022001219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190578.5A EP3772518A1 (en) 2019-08-07 2019-08-07 Modified human variable domains
PCT/NL2020/050496 WO2021025555A1 (en) 2019-08-07 2020-08-04 Modified human variable domains

Publications (1)

Publication Number Publication Date
MX2022001219A true MX2022001219A (es) 2022-03-02

Family

ID=67658530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001219A MX2022001219A (es) 2019-08-07 2020-08-04 Dominios variables humanos modificados.

Country Status (11)

Country Link
US (1) US20220281957A1 (es)
EP (2) EP3772518A1 (es)
JP (2) JP2022543852A (es)
KR (1) KR20220042218A (es)
CN (2) CN114245804A (es)
AU (1) AU2020326289A1 (es)
BR (1) BR112022002315A2 (es)
CA (1) CA3149365A1 (es)
IL (1) IL290368A (es)
MX (1) MX2022001219A (es)
WO (1) WO2021025555A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
DK1806407T3 (da) 2001-07-04 2010-08-16 Chromagenics Bv DNA-sekvenser med anti-repressoraktivitet
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
KR20110029156A (ko) 2008-06-27 2011-03-22 메뤼스 베.페. 항체 생산 비-인간 포유동물
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
MX2021007949A (es) 2018-12-31 2021-10-22 Merus Nv Dominios de union mixtos.

Also Published As

Publication number Publication date
BR112022002315A2 (pt) 2022-04-26
EP4010364A1 (en) 2022-06-15
CN114245804A (zh) 2022-03-25
IL290368A (en) 2022-04-01
KR20220042218A (ko) 2022-04-04
JP2023179537A (ja) 2023-12-19
WO2021025555A1 (en) 2021-02-11
CA3149365A1 (en) 2021-02-11
JP2022543852A (ja) 2022-10-14
US20220281957A1 (en) 2022-09-08
AU2020326289A1 (en) 2022-03-17
CN116333109A (zh) 2023-06-27
EP3772518A1 (en) 2021-02-10

Similar Documents

Publication Publication Date Title
EP3826612A4 (en) NOVEL MONOCLONAL ANTIBODIES SPECIFIC TO CLDN 18.2 AND THEIR METHODS OF USE
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
EP3712178A4 (en) ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
SA520411577B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
DE602006013029D1 (de) Anti-egfr-antikörper
MX2021004588A (es) Anticuerpo anti-cldn18.2 y sus usos.
WO2018031490A3 (en) Anti-ox40 binding proteins
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
MY196874A (en) Humanized anti-basigin antibodies and the use thereof
IL287232A (en) Humanized antibodies against c5 and bifunctional factor h fusion proteins and their uses
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
WO2017222556A3 (en) Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
EP3868783A4 (en) ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR THEREOF
PH12020550825A1 (en) Anti-c5 antibody combinations and uses thereof
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
MX2022003465A (es) Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana.
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
MX2022001219A (es) Dominios variables humanos modificados.
WO2020127354A3 (en) Polypeptides